Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures

COPD Clinical Trial

Official title:

Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02129309
• Other study ID #: ALPHa-COPD
• Status: Completed
• Phase: N/A
• First received: April 28, 2014
• Last updated: June 23, 2015
• Start date: June 2014
• Est. completion date: December 2014

Study information

• Verified date: January 2015
• Source: Cambridge University Hospitals NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Cambridge University Hospitals NHS Foundation Trust
• Study type: Interventional

Clinical Trial Summary

The investigators are interested in studying how Pulmonary Hypertension occurs. A substance called 'apelin', that naturally occurs in the body has been shown to have an important role in heart disease. Previous studies have shown that it can make blood vessels get wider, and help blood flow around the body and thus improve the way the heart and lungs work.

The investigators are looking to recruit both healthy and COPD pulmonary hypertension patients to study 3 types of apelin. The purpose of this study is to help the investigators understand how Pulmonary Hypertension occurs which may will help with the development of future treatments.

Description:

The purpose of this study:

To investigate the physiological role of apelin in the cardiovascular system in patients with COPD with raised pulmonary artery pressures.

Study Aim and hypotheses:

The primary objective is to test the above hypotheses using forearm blood flow and systemic infusions of apelin peptides.

Hypotheses:

1. Apelin agonists are vasodilators in human resistance vessels and this effect will be altered in patients with pulmonary hypertension.

2. Apelin peptides improve right ventricular and pulmonary haemodynamics in patients with elevated pulmonary artery pressures.

Study 1a - A validation dose study of 3 apelin agonists performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.

Study 1b- A validation dose study of apelin receptor antagonist, in healthy volunteers and COPD patients with elevated pulmonary artery pressures.

Study 2a - To define the haemodynamic response to apelin agonists in healthy volunteers and evaluate the response.

Study 2b - To investigate the haemodynamic response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers

• Aged 18 to 70 years

• Non-smoker (<1 cigarette per week)

• If female, postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test COPD patients with estimated Pulmonary Artery Pressure (PAP) on echo >25mmHg

• Clinical diagnosis of COPD as per standard criteria

• Between 18 and 70 years

• If female, postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test

Exclusion Criteria:

• pre-existing:

• Systemic Hypertension (sustained BP >160/100mmHg)

• Ischaemic Heart Disease

• Primary valvular heart disease

• Significant left ventricular failure

• Active malignancy

• Renal disease (Creatinine >180 µmol/L)

• Neurological disease

• Diabetes mellitus

• BMI >35, BMI <17

• Pregnancy

• Use of vasoactive medication or NSAIDS/aspirin within 48 hours of study.

• Current involvement in other research studies, other than observational/non-interventional

• Known HIV

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

• COPD
• Hypertension, Pulmonary
• Pulmonary Hypertension

Intervention

Procedure:
• Forearm plethysmography
Dose response study
• Haemodynamic studies
Dose response study

Locations

Country	Name	City	State
United Kingdom	Vascular Research Unit, Clinical Pharmacology Unit, ACCI, Level 3, Addenbrooke's Hospital, Hills Road	Cambridge

Sponsors (3)

Lead Sponsor	Collaborator
Cambridge University Hospitals NHS Foundation Trust	University of Cambridge, Wellcome Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Exploratory endpoints in Study 2 are systolic and diastolic blood pressure.		12 months	No
Primary	Percentage change in forearm blood flow in the infused arm. Forearm blood flow ratio in each arm, blood pressure and heart rate will also be reported.		12 months	No
Primary	Cardiac output and stroke volume, pulmonary vascular resistance, mean arterial pressure and heart rate.		12 months	No